FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2575985162> ?p ?o ?g. }

• W2575985162 endingPage "1906" @default.
• W2575985162 startingPage "1906" @default.
• W2575985162 abstract "Abstract Haemopoietic stem cell transplantation is a well-established treatment modality for haemoglobinopathies. The challenge is to minimise graft failure due to the expanded haemopoietic compartment whilst reducing the risk VOD due to the effects of iron load. From 2011 to 2015 fifty-four consecutive sibling transplants were conditioned with fludarabine 160 mg/m2, treosulfan 42 g/m2, thiotepa 10 mg/kg and ATG (Thymoglobulin) 7.5 mg/kg (FTTA). Endogenous haemopoiesis was suppressed pre-transplantation with hypertransfusions for a minimum of 8 weeks. GvHD prophylaxis was provided with ciclosporin and MMF. 33 patients were transplanted for b thalassaemia major and 21 for sickle cell disease. The median age was 7 years (2 - 16). The source of stem cells was BM in 49 patients and mixed cord blood and BM in 5 patients. The median cell dose was 3.48 x108 TNC/kg (range 0.23 - 8.51) and 6.73 x106 CD34+/kg (range 1.3 - 14.72) for the patients receiving bone marrow only; 1.64 x108 TNC/kg (range 1.22 - 3.9) and 4 x106 CD34+/kg (range 2.06 - 8.79) for BM and 3.8 x107 TNC/kg (range 0.8 - 7.32) and 0.53 x106 CD34+/kg (range 0.06 - 1.8) for cord blood for the patients receiving a combination of cord blood and bone marrow. The median survival was 14.4 months (1-41.9). Patients with thalassaemia were Pesaro class I or II (Pesaro class III patients were intensively chelated pre-transplantation to return to class I or II). Patients with sickle cell disease were transplanted for stroke or recurrent vaso-oclusive crises and/or acute chest syndrome not responding to hydroxycarbamide. All patients were evaluated with liver biopsy pre-transplantation and defibrotide prophylaxis given if Ishak stage ≥ 3. All patients engrafted and achieved evidence of donor haemopoiesis on day +28, and all but one patient achieved transfusion-independence and donor haematological values. One patient (1.9%) had progressive reduction of donor haemopoiesis with reestablishment of ineffective thalassaemic haemopoiesis and transfusion dependence on day +313. There were two deaths, one on day +89 due to idiopathic pneumonia syndrome in a patient with b thalassaemia major and one on day +189 due to an intracranial haemorrhage caused by refractory immune thrombocytopenia off immunosuppression in a patient with sickle cell disease and moya moya. Acute GvHD ≥ grade 2 occurred in 6 patients (11.1%). Chronic limited GvHD occurred in 7 patients (13%) and extensive in 3 patients (5.6%). Chronic GvHD was only present at 18 months in one patient (1.9%). VOD occurred in 2 patients (3.7%, days +7 and +9 respectively) and responded to standard measures and defibrotide treatment. The median neutrophil engraftment was 12 days (range 8 to 21). The median platelet engraftment >20 x109/L was 27 days (range 15 to 73) and >50 x109/L was 32 days (range 15 to 73). The median time to cessation of immunosuppression was 160 days (91-538). Chimerism studies on day +28 demonstrated 92.3% in whole blood (WB) and 69% in T cells (T) >95%, 5.8% WB and 4.8% T >90-95%, 1.9% WB and 21.4% T >50-89%, 0% WB and 4.8% T <50%; day +90: 83.3% WB and 60.4% T >95%, 4.2% WB and 8.4% T >90-95%, 10.4% WB and 20.8% T >50-89%, 2.1% WB and 10.4% T <50%; day +180: 59.4% WB and 45% T >95%, 19% WB and 17.5% T >90-95%, 16.7% WB and 35% T >50-89%, 4.8% WB and 2.5% T <50%; and day +365: 59.4% WB and 53.4% T >95%, 12.5% WB and 13.3% T >90-95%, 15.6% WB and 20% T >50-89%, 12.5% WB and 13.3% T <50%. In conclusion, FTTA leads to early and sustained engraftment with low rate of graft failure, and minimal occurrence of VOD whilst the incidence of GvHD is low. Disclosures No relevant conflicts of interest to declare." @default.
• W2575985162 created "2017-01-26" @default.
• W2575985162 creator A5000049478 @default.
• W2575985162 creator A5016006212 @default.
• W2575985162 creator A5026129590 @default.
• W2575985162 creator A5030095130 @default.
• W2575985162 creator A5039305143 @default.
• W2575985162 creator A5044310920 @default.
• W2575985162 creator A5051203301 @default.
• W2575985162 creator A5073567304 @default.
• W2575985162 creator A5074615510 @default.
• W2575985162 date "2015-12-03" @default.
• W2575985162 modified "2023-09-28" @default.
• W2575985162 title "Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in Haemoglobinopathies Leads to Early and Sustanined Engraftment with Low Incidence of VOD and GvHD" @default.
• W2575985162 doi "https://doi.org/10.1182/blood.v126.23.1906.1906" @default.
• W2575985162 hasPublicationYear "2015" @default.
• W2575985162 type Work @default.
• W2575985162 sameAs 2575985162 @default.
• W2575985162 citedByCount "0" @default.
• W2575985162 crossrefType "journal-article" @default.
• W2575985162 hasAuthorship W2575985162A5000049478 @default.
• W2575985162 hasAuthorship W2575985162A5016006212 @default.
• W2575985162 hasAuthorship W2575985162A5026129590 @default.
• W2575985162 hasAuthorship W2575985162A5030095130 @default.
• W2575985162 hasAuthorship W2575985162A5039305143 @default.
• W2575985162 hasAuthorship W2575985162A5044310920 @default.
• W2575985162 hasAuthorship W2575985162A5051203301 @default.
• W2575985162 hasAuthorship W2575985162A5073567304 @default.
• W2575985162 hasAuthorship W2575985162A5074615510 @default.
• W2575985162 hasConcept C126322002 @default.
• W2575985162 hasConcept C141071460 @default.
• W2575985162 hasConcept C2776694085 @default.
• W2575985162 hasConcept C2776755627 @default.
• W2575985162 hasConcept C2777408962 @default.
• W2575985162 hasConcept C2777630719 @default.
• W2575985162 hasConcept C2779178397 @default.
• W2575985162 hasConcept C2779263901 @default.
• W2575985162 hasConcept C2779968505 @default.
• W2575985162 hasConcept C2779972918 @default.
• W2575985162 hasConcept C2780007613 @default.
• W2575985162 hasConcept C2780303639 @default.
• W2575985162 hasConcept C2780611847 @default.
• W2575985162 hasConcept C2911091166 @default.
• W2575985162 hasConcept C71924100 @default.
• W2575985162 hasConcept C90924648 @default.
• W2575985162 hasConceptScore W2575985162C126322002 @default.
• W2575985162 hasConceptScore W2575985162C141071460 @default.
• W2575985162 hasConceptScore W2575985162C2776694085 @default.
• W2575985162 hasConceptScore W2575985162C2776755627 @default.
• W2575985162 hasConceptScore W2575985162C2777408962 @default.
• W2575985162 hasConceptScore W2575985162C2777630719 @default.
• W2575985162 hasConceptScore W2575985162C2779178397 @default.
• W2575985162 hasConceptScore W2575985162C2779263901 @default.
• W2575985162 hasConceptScore W2575985162C2779968505 @default.
• W2575985162 hasConceptScore W2575985162C2779972918 @default.
• W2575985162 hasConceptScore W2575985162C2780007613 @default.
• W2575985162 hasConceptScore W2575985162C2780303639 @default.
• W2575985162 hasConceptScore W2575985162C2780611847 @default.
• W2575985162 hasConceptScore W2575985162C2911091166 @default.
• W2575985162 hasConceptScore W2575985162C71924100 @default.
• W2575985162 hasConceptScore W2575985162C90924648 @default.
• W2575985162 hasIssue "23" @default.
• W2575985162 hasLocation W25759851621 @default.
• W2575985162 hasOpenAccess W2575985162 @default.
• W2575985162 hasPrimaryLocation W25759851621 @default.
• W2575985162 hasRelatedWork W2521295881 @default.
• W2575985162 hasRelatedWork W2588114258 @default.
• W2575985162 hasRelatedWork W2620956092 @default.
• W2575985162 hasRelatedWork W2743113491 @default.
• W2575985162 hasRelatedWork W2754125581 @default.
• W2575985162 hasRelatedWork W2978801764 @default.
• W2575985162 hasRelatedWork W2979901738 @default.
• W2575985162 hasRelatedWork W2987714777 @default.
• W2575985162 hasRelatedWork W4200579925 @default.
• W2575985162 hasRelatedWork W4210347081 @default.
• W2575985162 hasVolume "126" @default.
• W2575985162 isParatext "false" @default.
• W2575985162 isRetracted "false" @default.
• W2575985162 magId "2575985162" @default.
• W2575985162 workType "article" @default.